Atlantic Canada�s Value Proposition by 4210Zq3

VIEWS: 0 PAGES: 19

									        Atlantic Canada’s
        Value Proposition
Re$earch Money Conference
     November, 2007
   Halifax, Nova Scotia
Atlantic Canada’s Value Proposition
   Context to remarks
    •   Understanding BioVectra Inc. and Diagnostic Chemicals
        Limited
    •   Our in-house research capabilities and focus
    •   Our collaborations with Atlantic Canada researchers and
        organizations
    •   Our collaborations with Pharmaceutical and Diagnostic
        companies
DCL
and
BioVectra

            • Founded in 1970 by Dr. Regis Duffy
            • Privately held and controlled
            • DCL employs over 240 people in 3 countries
            • Four manufacturing facilities plus administration
              headquarters in Canada; sales and distribution
              offices in the United States and Mexico
            • Develops, manufactures and markets products
              worldwide
DCL and BioVectra
                    Prince Edward Island, Canada
                    • Manufacturing / Packaging
                    • Administration
                    • Research and Development
                    • Quality Control
                    • Regulatory Affairs
                    • Technical Services


                    Oxford, Connecticut
                    • Customer Services and Warehousing
                    • Field Sales and Technical Services


                    Mexico City, Mexico
                    • Customer Services and Warehousing

                    • Sales and Field Technical Services
                Corporate Overview
                Revenue 2003-2007
40,000
35,000
30,000
25,000
20,000
                                             Revenue
15,000
10,000
 5,000
    0
         2003    2004   2005   2006   2007
             DCL and BioVectra
        Actual and Projected Revenue
60000

50000

40000

30000
                                                         Revenue
20000

10000

   0
        2003   2004   2005   2006   2007   2008   2009
Diagnostics
Develops, manufactures and markets worldwide:
•   Chemistry reagents for human and veterinary diagnostics
•   Specialty / Niche chemistry reagents for human and veterinary diagnostics
•   Immunochromatographic point-of-care assays
•   Laboratory consumable manufacturing on a contract basis



                                        Provides services in:
                                        •   Contract Sales and Distribution
                                        •   Custom product formulations/manufacturing
                                        •   Lyophilization, dry and liquid blending
                                        •   Full kitting including dispensing and labeling
                                        •   Applications development / FDA filing
Diagnostics Strategy


 R & D:
             External Collaboration
          •      Diagnostic companies with problem chemistries
          •      Universities with technologies in clinical
                 chemistry
          •      Small firms or individuals with unique chemistries
             Internal Activities
          •      focus on product development
Diagnostics
    – keys to success

   Focus on Manufacturing Excellence
   Unique Products
   Customer Service
   Human capital


      A very good fit with Genzyme Corporation
•   BioVectra is a cGMP manufacturer of
    APIs and advanced intermediates
•   Fermentation
•   Bioextractions and purifications
•   PEG reagents & PEGylation services
•   Specialty biochemicals and enzymes
•   Creating partnerships with others
    utilizing our applied technologies to
    improve or enhance new and existing
    products
BioVectra

            R & D:
               External collaboration
                 •   Pharma and Biotech
                     companies with unique
                     problems
                 •   Universities
                 •   NRC-INH
                 •   Drug discovery companies
  BioVectra

R & D:
    Internal Activities
       •   PEGs ( a product used as part of the
           drug, to extend stability and improve
           performance )
       •   Taxanes – to gain an advantage in
           generic introduction of a semi-synthetic
           version of a major oncology drug
       •   New Drug Development program – a
           structure to invest in development of
           selected candidates
BioVectra
            Keys to Success:

               •   Focus on Manufacturing
                   Excellence
               •   Unique Products
               •   Customer Service
               •   Human Capital
Atlantic Canada’s Value Proposition

                North American strategic location
                Good cost base for technical
                 activities and manufacturing
                Quality of life for employees is
                 appreciated and creates loyalty
                Low bureaucracy, ‘can-do’
                 attitude
                Excellent public support climate
                Institutional support - NRC, AVC,
                 Universities
Atlantic Canada Value Proposition
                 Strong support and collaborative
                  system in place; example - PEI
                  BioAlliance

                 Canadian Business 2007 ranked
                  Charlottetown as the 2nd best place to
                  do business in Canada

                 Provincial Tax Incentives – Corporate
                  tax, HR Recruitment support

                 ACOA Atlantic Innovation Fund (AIF)
                  reduces product development risks
Some challenges

   Experience base is limited among available labor
   Challenging to retain young mobile talent
   Must overcome perceptions of remote location – access
    is an issue
   Removed from financial sources typically used by
    competition
    Atlantic Canada’s Value Proposition
   Atlantic Canada can contribute
    to the national science and
    business goals

   Think about it;
     • Strong university
       environment
     • Well educated work force
     • Strong work ethic
     • Entrepreneurial spirit
     • Local government willing to
       support economic innovation
    Atlantic Canada’s Value Proposition
Some comments:
   Message to Governments –
    “Atlantic Canada is stepping up” as
    a serious business contender in
    the science area
   ACOA- AIF is an important tool for
    technology transfer and
    commercialization
   Maintain and improve competitive
    tax incentives for science based
    businesses
   Develop policies and incentives to
    attract world-class researchers and
    highly qualified personnel
   Invest more in infrastructure and
    less on strategic forms
        Atlantic Canada’s Value Proposition

   This sector is an opportunity for Atlantic Canada to
    shine – We are committed to making this happen

								
To top